EHA 2016 | Current news in MCL – allogeneic transplants
Simon Rule, MD from Derriford Hospital, Plymouth, UK discusses current mantle cell lymphoma (MCL) news, including the novel results from clinical trials using ibrutinib and frontline allogeneic stem cell transplantation. Allogeneic transplant is often not the first-line of treatment due to its toxicity. Instead, treatment for younger patients involves chemotherapy then an autologous stem cell transplant, however, patients often still relapse. Prof Rule discusses his clinical trial (NCT00720447) of 25 patients undergoing an allogeneic transplant with a transplant rate of mortality of 8% and progression-free survival (PFS) 3 years rate of 70%. This suggests that there may be a potential application for patients who are struggling with conventional therapy. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Get great new content delivered to your inboxSign up